KRYS vs ABBV

For growth investors, Krystal Biotech, Inc.

(KRYS) is the stronger pick with 33. 9% revenue growth year-over-year, versus 8. 6% for AbbVie Inc. (ABBV). Krystal Biotech, Inc. (KRYS) offers the better valuation at 43. 4x trailing P/E (39. 3x forward), making it the more compelling value choice. Analysts rate Krystal Biotech, Inc. (KRYS) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Krystal Biotech, Inc.

(KRYS) is the cheapest at 43. 4x versus AbbVie Inc. at 85. 5x. On forward P/E, AbbVie Inc. is actually cheaper at 14. 3x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Krystal Biotech, Inc.

(KRYS) delivered a total return of +319. 2%, compared to +101. 3% for AbbVie Inc. (ABBV). Over 10 years, the gap is even starker: KRYS returned +26. 9% versus ABBV's +295. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 34β versus Krystal Biotech, Inc. 's 1. 12β — meaning KRYS is approximately 232% more volatile than ABBV relative to the S&P 500.

By revenue growth (latest reported year), Krystal Biotech, Inc.

(KRYS) is pulling ahead at 33. 9% versus 8. 6% for AbbVie Inc. (ABBV). On earnings-per-share growth, the picture is similar: Krystal Biotech, Inc. grew EPS 128. 0% year-over-year, compared to -0. 8% for AbbVie Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Krystal Biotech, Inc.

(KRYS) is the more profitable company, earning 52. 6% net margin versus 6. 9% for AbbVie Inc. — meaning it keeps 52. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KRYS leads at 41. 5% versus 32. 8% for ABBV. At the gross margin level — before operating expenses — KRYS leads at 92. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, AbbVie Inc.

(ABBV) trades at 14. 3x forward P/E versus 39. 3x for Krystal Biotech, Inc. — 25. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ABBV: 26. 6% to $256. 64.

In this comparison, ABBV (3.

2% yield) pays a dividend. KRYS does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Both have compounded well over 10 years (ABBV: +295. 5%, KRYS: +26. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KRYS is a small-cap high-growth stock; ABBV is a large-cap income-oriented stock. ABBV pays a dividend while KRYS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.